{"id":118265,"date":"2026-06-15T16:55:41","date_gmt":"2026-06-15T11:25:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=118265"},"modified":"2026-06-15T16:55:42","modified_gmt":"2026-06-15T11:25:42","slug":"aurobindo-pharma-share-price-eugia-usfda-oai-june-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/","title":{"rendered":"Aurobindo Pharma Share Price Falls 5% After USFDA Classifies Eugia Unit as OAI"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Aurobindo Pharma share price down over 5% on June 15. Eugia Unit-III OAI after Jan-Feb 2026 USFDA inspection. 11 observations. 52W high Rs 1,550.<\/em><\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today?params=auropharma&amp;params=aurobindo-pharma-ltd-share-price-today&amp;cacheClear=1781522646855\">Aurobindo Pharma<\/a> share price<\/strong> declined over 5% on June 15, 2026, as markets continued to react to the USFDA&#8217;s classification of Eugia Unit-III, a formulation manufacturing facility of wholly-owned subsidiary Eugia Pharma Specialities Ltd, as Official Action Indicated (OAI). The announcement was made on June 13, 2026, after the regulator reviewed its January-February 2026 inspection at which 11 observations were issued. The OAI is the most serious USFDA inspection outcome and indicates potential regulatory action ahead.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=aurobindo-pharma-eugia-usfda-oai\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#USFDA_OAI_Classification_Full_Details_of_the_Eugia_Unit-III_Inspection\" title=\"USFDA OAI Classification: Full Details of the Eugia Unit-III Inspection\">USFDA OAI Classification: Full Details of the Eugia Unit-III Inspection<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#What_OAI_Means_and_Why_Aurobindo_Pharma_Share_Price_Fell_Over_5\" title=\"What OAI Means and Why Aurobindo Pharma Share Price Fell Over 5%\">What OAI Means and Why Aurobindo Pharma Share Price Fell Over 5%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#Aurobindo_Pharma_Financial_Performance_and_US_Market_Exposure\" title=\"Aurobindo Pharma Financial Performance and US Market Exposure\">Aurobindo Pharma Financial Performance and US Market Exposure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#Why_did_Aurobindo_Pharma_share_price_fall_on_June_15_2026\" title=\"Why did Aurobindo Pharma share price fall on June 15, 2026?\">Why did Aurobindo Pharma share price fall on June 15, 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#What_is_OAI_classification_and_what_does_it_mean_for_Aurobindo_Pharma\" title=\"What is OAI classification and what does it mean for Aurobindo Pharma?\">What is OAI classification and what does it mean for Aurobindo Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#What_is_Eugia_Pharma_Specialities_and_which_facility_received_the_OAI\" title=\"What is Eugia Pharma Specialities and which facility received the OAI?\">What is Eugia Pharma Specialities and which facility received the OAI?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#How_many_observations_did_the_USFDA_issue_at_Eugia_Unit-III\" title=\"How many observations did the USFDA issue at Eugia Unit-III?\">How many observations did the USFDA issue at Eugia Unit-III?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#Has_Aurobindo_Pharmas_Eugia_Unit-III_faced_OAI_classification_before\" title=\"Has Aurobindo Pharma&#8217;s Eugia Unit-III faced OAI classification before?\">Has Aurobindo Pharma&#8217;s Eugia Unit-III faced OAI classification before?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#What_is_the_potential_impact_of_the_OAI_on_Aurobindo_Pharmas_US_business\" title=\"What is the potential impact of the OAI on Aurobindo Pharma&#8217;s US business?\">What is the potential impact of the OAI on Aurobindo Pharma&#8217;s US business?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#What_is_Aurobindo_Pharmas_financial_performance\" title=\"What is Aurobindo Pharma&#8217;s financial performance?\">What is Aurobindo Pharma&#8217;s financial performance?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-eugia-usfda-oai-june-2026\/#Should_I_sell_Aurobindo_Pharma_shares_after_the_OAI_news\" title=\"Should I sell Aurobindo Pharma shares after the OAI news?\">Should I sell Aurobindo Pharma shares after the OAI news?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"USFDA_OAI_Classification_Full_Details_of_the_Eugia_Unit-III_Inspection\"><\/span><strong>USFDA OAI Classification: Full Details of the Eugia Unit-III Inspection<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The USFDA conducted a cGMP inspection at Eugia Unit-III from January 27 to February 6, 2026. At conclusion, the regulator issued 11 observations. After reviewing <a href=\"https:\/\/univest.in\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a>&#8216;s responses, the USFDA determined the outcome as OAI and the company notified stock exchanges on June 13, 2026. The table below summarises the regulatory event in full.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #000000;\">\n<th style=\"color: #ffffff; padding: 8px 12px; text-align: left; font-size: 13px;\">Parameter<\/th>\n<th style=\"color: #ffffff; padding: 8px 12px; text-align: left; font-size: 13px;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Facility<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Eugia Unit-III (Formulation manufacturing), Pashamylaram, Telangana<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Entity<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Eugia Pharma Specialities Ltd (wholly-owned subsidiary of Aurobindo Pharma)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">USFDA Inspection Dates<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">January 27 to February 6, 2026<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Observations Issued<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">11 observations at inspection conclusion<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Classification<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Official Action Indicated (OAI)<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Announcement Date<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">June 13, 2026 (exchange filing by Aurobindo Pharma)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px 32px; margin: 24px 0; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,sans-serif; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0; line-height: 1.3;\">3 Stocks Building Serious Momentum Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">When <strong style=\"color: #0a0a23;\">Univest analysts<\/strong> identify high-conviction stock opportunities, <em>investors pay attention.<\/em><\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">Our research team has now shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on current market momentum, sector trends &amp; growth potential for 2026.<\/p>\n<ul style=\"margin: 0 0 16px 20px; padding: 0; color: #3a3a5c; font-size: 15px; line-height: 1.8;\">\n<li>Discover stocks investors are actively accumulating<\/li>\n<li>High-conviction opportunities backed by research<\/li>\n<li>Designed for the next phase of market growth<\/li>\n<\/ul>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/log-in?redirectUrl=%2Fuser%2Fpayment%3FplanType%3DALL_PRO%2BPLANS%26cacheClear%3D1780639629052\">Top Stock Picks<\/a> on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; letter-spacing: 0.2px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=aurobindo-pharma-eugia-usfda-oai\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_OAI_Means_and_Why_Aurobindo_Pharma_Share_Price_Fell_Over_5\"><\/span><strong>What OAI Means and Why Aurobindo Pharma Share Price Fell Over 5%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>OAI is the most serious of three USFDA inspection classifications. It signals that the regulator found significant objectionable conditions and believes administrative or regulatory sanctions are warranted. For <strong>Aurobindo Pharma share price<\/strong>, the OAI raises two concerns.<\/p>\n<p>First, OAI often precedes a USFDA Warning Letter, which can restrict new drug application approvals from the affected facility and potentially trigger import alerts. Second, Eugia Unit-III has a history of serious USFDA scrutiny: it received an OAI in May 2024, followed by a Warning Letter in August 2024. A second OAI cycle within two years at the same facility raises systemic quality management questions.<\/p>\n<p>Ankit Jaiswal, Senior Research Analyst at Univest, notes that <strong>Aurobindo Pharma share price<\/strong> had recovered strongly from its 52-week low of Rs 1,016.10 before this regulatory setback. He flags that the key question for investors is whether the USFDA will issue a Warning Letter as a follow-up to this OAI, which would be a more material escalation for US revenue from Eugia Unit-III.<\/p>\n<p>Kunal Singla, Associate Director at Univest, observes that Aurobindo&#8217;s diversified multi-facility manufacturing base means a single facility OAI does not threaten overall US revenues. However, the repetitive nature of serious compliance observations at Eugia Unit-III specifically warrants close monitoring of the USFDA&#8217;s subsequent enforcement steps.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track live Aurobindo Pharma share price and pharma regulatory news on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Financial_Performance_and_US_Market_Exposure\"><\/span><strong>Aurobindo Pharma Financial Performance and US Market Exposure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma reported FY26 total revenues of Rs 33,384 crore, up 6.39% year on year. The US accounts for approximately 40 to 45 percent of consolidated revenues. Eugia Pharma Specialities operates multiple manufacturing units, and the company has historically managed USFDA classification issues through comprehensive corrective action plans submitted post-inspection.<\/p>\n<p>The company stated in its exchange filing that it is committed to maintaining the highest quality manufacturing standards at all facilities globally. The 11 inspection observations at Eugia Unit-III and the USFDA&#8217;s decision to classify them as OAI suggest the responses to those observations were considered insufficient at this stage.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aurobindo Pharma share price live and monitor pharma regulatory news.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma share price fell over 5% on June 15, 2026, after the USFDA classified Eugia Unit-III as OAI following a January-February 2026 inspection with 11 observations. This is the most serious USFDA inspection outcome and raises the risk of further regulatory escalation including a potential Warning Letter, as happened previously at the same facility in 2024. Ankit Jaiswal and Kunal Singla at Univest recommend monitoring whether the USFDA issues a Warning Letter as the next critical trigger for Aurobindo Pharma share price direction.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Aurobindo_Pharma_share_price_fall_on_June_15_2026\"><\/span><strong>Why did Aurobindo Pharma share price fall on June 15, 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma share price fell over 5% on June 15, 2026, after the USFDA classified Eugia Unit-III, a formulation manufacturing facility of Eugia Pharma Specialities, as OAI. The OAI classification was disclosed on June 13, 2026, and the market continued to react on June 15 as investors assessed the potential regulatory escalation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_OAI_classification_and_what_does_it_mean_for_Aurobindo_Pharma\"><\/span><strong>What is OAI classification and what does it mean for Aurobindo Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> OAI stands for Official Action Indicated. It is the most serious of three USFDA inspection outcomes: NAI (No Action Indicated), VAI (Voluntary Action Indicated), and OAI. OAI means the USFDA found significant objectionable conditions and administrative or regulatory action is indicated, which can include Warning Letters or import alerts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Eugia_Pharma_Specialities_and_which_facility_received_the_OAI\"><\/span><strong>What is Eugia Pharma Specialities and which facility received the OAI?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Eugia Pharma Specialities Ltd is a wholly-owned subsidiary of Aurobindo Pharma. The OAI classification was for its Unit-III facility, a formulation manufacturing plant at Pashamylaram, Sangareddy District, Telangana. The USFDA inspected this facility from January 27 to February 6, 2026, issuing 11 observations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_many_observations_did_the_USFDA_issue_at_Eugia_Unit-III\"><\/span><strong>How many observations did the USFDA issue at Eugia Unit-III?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The USFDA issued 11 observations at the conclusion of its inspection of Eugia Unit-III, conducted from January 27 to February 6, 2026. The nature and number of these observations led the regulator to classify the facility as OAI after reviewing the company&#8217;s responses.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Has_Aurobindo_Pharmas_Eugia_Unit-III_faced_OAI_classification_before\"><\/span><strong>Has Aurobindo Pharma&#8217;s Eugia Unit-III faced OAI classification before?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes. Eugia Unit-III previously received an OAI classification in May 2024. That classification was subsequently followed by a USFDA Warning Letter in August 2024. The current OAI relates to a fresh inspection cycle in early 2026 and is a separate regulatory event.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_potential_impact_of_the_OAI_on_Aurobindo_Pharmas_US_business\"><\/span><strong>What is the potential impact of the OAI on Aurobindo Pharma&#8217;s US business?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> An OAI classification can lead to a Warning Letter, import alerts, or restrictions on new drug application approvals from the affected facility. Aurobindo Pharma has stated it is committed to maintaining the highest quality standards and will work closely with the USFDA to address the inspection findings comprehensively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Aurobindo_Pharmas_financial_performance\"><\/span><strong>What is Aurobindo Pharma&#8217;s financial performance?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma reported FY26 total revenues of Rs 33,384 crore, up 6.39% year on year from Rs 31,378 crore in FY25. The US is the company&#8217;s largest single revenue contributor. The company is one of India&#8217;s leading generic pharmaceutical exporters with operations across multiple facilities in India, the US, and Europe.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_sell_Aurobindo_Pharma_shares_after_the_OAI_news\"><\/span><strong>Should I sell Aurobindo Pharma shares after the OAI news?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investment decisions on Aurobindo Pharma share price should consider the severity of the OAI findings, the remediation timeline, and potential impact on US revenue from Eugia Unit-III. OAI classifications have been resolved by companies with corrective action plans in the past. Always consult a SEBI-registered investment adviser before acting on regulatory news.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma share price fell over 5% on June 15, 2026, after USFDA classified Eugia Unit-III as OAI following 11 observations in a Jan-Feb 2026 inspection. Ankit Jaiswal and Kunal Singla at Univest explain the OAI risk, prior history at the same facility, and outlook.<\/p>\n","protected":false},"author":28,"featured_media":118289,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3818],"class_list":["post-118265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-falling"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1781522745:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["74"],"rank_math_title":["Aurobindo Pharma Share Price Falls 5% After USFDA Classifies Eugia Unit as OAI"],"rank_math_description":["Aurobindo Pharma share price fell over 5% on June 15, 2026, after USFDA classified Eugia Unit-III at Pashamylaram, Telangana, as OAI following 11 observations in a January-February 2026 inspection."],"rank_math_focus_keyword":["Aurobindo Pharma share price"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["118289"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["18066"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Aurobindo-Pharma-Share-Price-Falls.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=118265"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118265\/revisions"}],"predecessor-version":[{"id":118291,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118265\/revisions\/118291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/118289"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=118265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=118265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=118265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}